Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
- Merck & Co Inc (NYSE:MRK) announced results from the pivotal Phase 3 KEYNOTE-859 trial of Keytruda (pembrolizumab) with fluoropyrimidine- and platinum-containing chemotherapy for gastric cancers.
- The trial covers the treatment of patients for the first-line treatment of human epidermal growth factor receptor 2 (HER2)-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.
- Related: Merck's Keytruda Plus Chemo Combo Aces Late-Stage Study In Advanced Endometrial Cancer Patients.
- After a median follow-up of 31.0 months (range, 15.3-46.3 months), Keytruda/chemo combo significantly improved overall survival (OS), reducing the risk of death by 22% compared to chemotherapy alone for these patients, regardless of PD-L1 expression.
- Median OS was 12.9 months for Keytruda/chemo combo versus 11.5 months for chemotherapy alone.
- Keytruda/chemo combo reduced the risk of disease progression or death by 24% with a median PFS of 6.9 months compared to 5.6 months for chemotherapy alone.
- The objective response rate was 51.3%, with a complete response (CR) rate of 9.5% and a partial response (PR) rate of 41.8%, for the Keytruda/chemo combo and 42.0%, with a CR rate of 6.2% and a PR rate of 35.7%, for those who received chemotherapy alone.
- Price Action: MRK shares are down 0.44% at $107.21 on the last check Thursday.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!